HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yoshida, T. Articles by Kondo, M. Search for Related Content PubMed Articles by Yoshida, T. Articles by Kondo, M.

Anti-obesity effect of CL 316,243, a highly specific β₃-adrenoceptor agonist, in mice with monosodium-L-glutamate-induced obesity

Yoshida T. Sakane N, Wakabayashi Y, Umekawa T, Kondo M. Anti-obesity effect of CL 316,243, a highly specific β₃-adrenoceptor agonist, in mice with monosodium-L-glutamate-induced obesity. Eur J Endocrinol 1994;131:97–102. ISSN 0804–4643.

The effects of CL 316,243, a highly specific β₃-adrenoceptor agonist (relative selectivities of 0, 1 and 100000 for β₁-, β₂- and β₃-receptors, respectively), were evaluated in mice with monosodium L-glutamate (MSG)-induced obesity as well as in control mice injected with physiological saline instead of MSG. Both MSG- and saline-treated mice were divided into three groups and at 8 weeks of age received either CL 316,243 (0.1 or 1.0 mg/kg) or distilled water through a gastric tube for 2 weeks. CL 316,243 not only reduced white adipose tissue mass but also activated brown adipose tissue and systemic metabolism, and hence reduced body mass without affecting food intake. Furthermore, CL 316,243 decreased hyperglycemia and hypertriglyceridemia in MSG-treated mice. However, at the higher dose, CL 316,243 also increased liver triglyceride in MSG-treated mice. These observations suggest that CL 316,243 exerts an anti-obesity effect in mice with MSG-induced obesity and consequently may prove efficacious in the treatment of human obesity.

Toshihide Yoshida, First Department of Internal Medicine, Kyoto Prefectural University of Medicine, 465-Kajiicho, Hirokoji-Kawaramachi, Kamikyo-ku, Kyoto 602, Japan

This article has been cited by other articles:

				H. Kim, P. A. Pennisi, O. Gavrilova, S. Pack, W. Jou, J. Setser-Portas, J. East-Palmer, Y. Tang, V. C. Manganiello, and D. LeRoith Effect of adipocyte beta3-adrenergic receptor activation on the type 2 diabetic MKR mice Am J Physiol Endocrinol Metab, June 1, 2006; 290(6): E1227 - E1236. [Abstract] [Full Text] [PDF]

				J. Wilsey, S. Zolotukhin, V. Prima, and P. J. Scarpace Central leptin gene therapy fails to overcome leptin resistance associated with diet-induced obesity Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2003; 285(5): R1011 - R1020. [Abstract] [Full Text] [PDF]

				T. Yoshida, T. Umekawa, K. Kumamoto, N. Sakane, A. Kogure, M. Kondo, Y. Wakabayashi, T. Kawada, I. Nagase, and M. Saito beta 3-Adrenergic agonist induces a functionally active uncoupling protein in fat and slow-twitch muscle fibers Am J Physiol Endocrinol Metab, March 1, 1998; 274(3): E469 - E475. [Abstract] [Full Text] [PDF]